Hemispherx to Present at the 30th Annual ROTH Conference

ORLANDO, Fla., March 05, 2018 -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the 30^th Annual ROTH Conference on Monday, March 12^th at 5:30PM PT in Green – Salon 3 (the time may be subject to changes depending on the conference organizers) at the Ritz Carlton in Dana Point, California. The Company webcast can be found at http://wsw.com/webcast/roth32/heb/ following the presentation on March 12^th. Thomas K. Equels, M.S. J.D., Chief Executive Officer of Hemispherx Biopharma, will be presenting as well as meeting with investors one-on-one. Mr. Equels’ presentation will focus on ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome), immuno-oncology, and immune system amplification for enhanced viral vaccines. Each market is estimated in the billions.

Hemispherx has two flagship products: Alferon N Injection® and the experimental therapeutic Ampligen®. The Company also has six orphan drug designations with four in the U.S. and two in the European Union. Ampligen® has the potential to address multiple indications including ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome), influenza, ovarian cancer, melanoma, renal cell carcinoma and other indications. Alferon N Injection® also addresses multiple potential indications including HIV, HCV and MERS.

The 30^th Annual ROTH Conference, with close to 550 participating companies and over 4,700 attendees, will feature presentations from public and private companies in a variety of sectors including: Business Services, Cleantech, Industrial Growth & Solar, Consumer, Healthcare, Resources: Oil & Gas / Metals & Mining, Technology, Internet & Media.

About Hemispherx Biopharma
Hemispherx Biopharma, Inc., is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life-threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.

Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contact
Hemispherx Biopharma
Phone Number: 800-778-4042
Email: [email protected]